Drug recall · April 12, 2023
Testosterone Cypionate Injection recall
Why: cGMP: complaints of crystals not redissolving into solution after warming and shaking the vials.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Testosterone Cypionate Injection, USP, CIII, 200 mg/mL, packaged in: a) 10 mL multiple-dose vials (NDC 52536-625-10) and b) 1 mL single dose vials (NDC 52536-625-01), Rx only, Mfd for: Wilshire Pharmaceuticals, Inc., Atlanta, GA 30328.
- Lots / codes
Lot #23804.034A, 23803.061A, Exp 9/2024
- Quantity
- a) 16,471 vials; b) 43,096 vials
- Company
- Azurity Pharmaceuticals, Inc., Wilmington, MA
- Distribution
- US Nationwide
- Initiated
- February 15, 2023 · Voluntary: Firm initiated
- Classified
- March 31, 2023
- Reported
- April 12, 2023
- Ended
- December 4, 2023
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Testosterone
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.